Navigation Links
Bone Drugs May Beat Back Breast Cancer
Date:12/10/2009

Bisphosphonates seem to prevent recurrence, researchers find

THURSDAY, Dec. 10 (HealthDay News) -- Bone-building drugs used by tens of millions of women to fight osteoporosis also cut the risk of breast cancer, suggesting the drugs may play a dual role in keeping women healthy.

"Bone loss and potential fractures are a known complication of breast cancer therapy. Our feeling is that bisphosphonates may actually prevent disease recurrence through a variety of mechanisms," said Dr. Adam Brufsky, associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Brufsky authored one of several studies exploring the role of bone-building drugs in breast cancer prevention that were to be presented Thursday at the San Antonio Breast Cancer Symposium.

Bisphosphonates are already used to treat complications that result from breast cancer spreading to the bones.

One study looked at more than 150,000 postmenopausal women who participated in the U.S. government-led Women's Health Initiative (WHI).

The women taking bisphosphonates, namely Fosamax (alendronate), had a 32 percent reduction in their rate of invasive breast cancer compared to women who were not taking one of these drugs.

The University of California, Los Angeles, researchers were able to control for the fact that women with low bone mineral density are already at lower risk for breast cancer.

Because the study was not a randomized, controlled one, said lead investigator Dr. Rowan Chlebowski, a professor and medical oncologist with UCLA, "the findings are not definitive but they do provide a strong signal."

In another study, Israeli researchers found that postmenopausal women taking bisphosphonates for one or more years had a 29 percent reduction in their risk of breast cancer.

And the tumors that did appear tended to be estrogen receptor-positive and thus easier to treat than estrogen receptor-negative tumors.

And in other news from the symposium:

  • Researchers from the University of Pittsburgh Cancer Institute, led by Brufsky, concluded that zoledronic acid, another bisphosphonate, is safe and effective for use by postmenopausal women with breast cancer who are being treated with aromatase inhibitors. Bone mineral density increased 6.2 percent in women taking zoledronic acid, compared with 2.4 percent in the control group. Fractures were also reduced slightly in the treatment group, but it's unclear how significant this was. Zoledronic acid is marketed under several brand names, including Zometa.
  • A new drug, denosumab, a monoclonal antibody, performed better than zoledronic acid in easing problems associated with the spread of breast cancer to the bones.
  • A final study found that it was safe to give zoledronic acid to women with breast cancer being treated with the aromatase inhibitor Femara (letrozole) before surgery. No clear indication emerged as to whether the dual treatment was effective, however.

More information

The National Cancer Institute has more on breast cancer.



SOURCES: Dec. 9, 2009, teleconference with: Rowan Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, and Adam Brufsky, M.D., Ph.D., associate professor, medicine, associate chief, hematology-oncology, and associate director, clinical investigation, University of Pittsburgh Cancer Institute


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AIDS Drugs Dont Need Routine Lab Monitoring
2. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
3. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
4. OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
5. Second-line CML drugs evoke faster response than front-line therapy
6. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
7. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
8. Diabetes Drugs Go Head-to-Head in Study
9. drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
10. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
11. Coverage of inexpensive drugs may increase length and quality of life after heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
Breaking Medicine Technology: